Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Apalutamide
Drug: Abiraterone
Drug: ADT
Drug: Prednisone

First Posted Date: 2016-08-15

Last Posted Date: 2021-07-07

Lead Sponsor: Latin American Cooperative Oncology Group

Target Recruit Count: 128

Registration Number: NCT02867020

Locations: 🇧🇷
Beneficiencia Portuguesa de São Paulo/Hospital São José, São Paulo, Brazil
🇧🇷
Hospital Erasto Gaertner, Curitiba, Paraná, Brazil
🇧🇷
IBCC, São Paulo, Brazil

and more 11 locations

EDOCH Alternating With DHAP for New Diagnosed Younger MCL

Phase 4

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Etoposide
Drug: Cytarabine
Drug: Thalidomide
Drug: Doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide
Drug: Prednisone
Drug: Cisplatin
Drug: Vincristine
Drug: Rituximab

First Posted Date: 2016-08-08

Last Posted Date: 2019-06-14

Lead Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Target Recruit Count: 55

Registration Number: NCT02858804

Locations: 🇨🇳
Shuhua Yi, Tianjin, China

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Phase 2

Terminated

Conditions: Transformed Lymphoma / DLBCL
Diffuse, Large B-Cell, Lymphoma
Follicular Lymphoma, Grade 3b

Interventions: Drug: denintuzumab mafodotin
Drug: rituximab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: vincristine
Drug: prednisone

First Posted Date: 2016-08-04

Last Posted Date: 2019-03-11

Lead Sponsor: Seagen Inc.

Target Recruit Count: 24

Registration Number: NCT02855359

Locations: 🇵🇷
Ponce Medical School Foundation, Ponce, Puerto Rico
🇺🇸
Hollings Cancer Center, Charleston, South Carolina, United States
🇺🇸
Northwest Medical Specialties, PLLC, Tacoma, Washington, United States

and more 32 locations

A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy

Phase 2

Completed

Conditions: Stage III Prostate Cancer AJCC v7
Stage IV Prostate Cancer AJCC v7
Stage III Prostate Adenocarcinoma AJCC v7
Stage IV Prostate Adenocarcinoma AJCC v7

Interventions: Drug: Abiraterone Acetate
Drug: Apalutamide
Drug: Degarelix
Drug: Indomethacin
Other: Laboratory Biomarker Analysis
Drug: Prednisone

First Posted Date: 2016-07-29

Last Posted Date: 2022-01-13

Lead Sponsor: University of Washington

Target Recruit Count: 22

Registration Number: NCT02849990

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Hormone-Resistant Prostate Cancer
Stage IV Prostate Adenocarcinoma

Interventions: Drug: Cabazitaxel
Drug: Prednisone

First Posted Date: 2016-07-26

Last Posted Date: 2021-01-25

Lead Sponsor: University of California, Davis

Target Recruit Count: 2

Registration Number: NCT02844582

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone

Phase 1

Withdrawn

Conditions: Acute Lymphoblastic Leukemia

Interventions: Drug: Ibrutinib
Drug: Dasatinib
Drug: Prednisone

First Posted Date: 2016-06-28

Last Posted Date: 2018-01-31

Lead Sponsor: University of Utah

Registration Number: NCT02815059

Locations: 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States

Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients

Phase 4

Conditions: Neuromyelitis Optica Spectrum Disorders
Efficacy and Safety
Mycophenolate Mofetil

Interventions: Drug: Mycophenolate mofetil
Drug: Prednisone

First Posted Date: 2016-06-22

Last Posted Date: 2016-06-22

Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 100

Registration Number: NCT02809079

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Phase 1

Completed

Conditions: Peripheral T-cell Lymphoma

Interventions: Drug: Chidamide
Drug: cyclophosphamide
Drug: adriacin
Drug: vincristine
Drug: prednisone

First Posted Date: 2016-06-22

Last Posted Date: 2019-07-24

Lead Sponsor: Chipscreen Biosciences, Ltd.

Target Recruit Count: 30

Registration Number: NCT02809573

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Recurrent Prostate Carcinoma
Stage IV Prostate Cancer
Metastatic Prostate Carcinoma

Interventions: Drug: Abiraterone Acetate
Drug: Niclosamide
Drug: Prednisone

First Posted Date: 2016-06-21

Last Posted Date: 2024-12-18

Lead Sponsor: Mamta Parikh

Target Recruit Count: 37

Registration Number: NCT02807805

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)

Phase 2

Completed

Conditions: Acute GVHD

Interventions: Drug: Prednisone
Drug: Sirolimus

First Posted Date: 2016-06-21

Last Posted Date: 2021-11-01

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 127

Registration Number: NCT02806947

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Blood & Marrow Transplant Program at Northside Hospital, Atlanta, Georgia, United States

and more 18 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy